Difenoximide hydrochloride

Application L-Glutamic acid &#947-(p-nitroanilide) hydrochloride has been used as a solute carrier family 1 member 5 (SLC1A5) inhibitor: or an inhibitor of the cell membrane glutamine transporter to study the effects of blocking glutamine uptake

Lometrexol (DDATHF) disodium, an antipurine antifolate , can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol disodium can further inhibit de novo

Lometrexol (DDATHF) disodium, an antipurine antifolate , can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol disodium can further inhibit de novo

Lometrexol (DDATHF) disodium, an antipurine antifolate , can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol disodium can further inhibit de novo

A full agonist of the serotonin 5-HT7 receptor (Ki = 0.22 nM) that displays 200- and greater than 1,000-fold selectivity over 5-HT1A (Ki = 52.

Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1.A Cox-2 selective inhibitor and NSAID.

Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1.A Cox-2 selective inhibitor and NSAID.

Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1.A Cox-2 selective inhibitor and NSAID.

Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1.A Cox-2 selective inhibitor and NSAID.

Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1.A Cox-2 selective inhibitor and NSAID.

InformationLumiracoxib (COX-189) is a novel, selectiveCOX-2inhibitor withKiof 0.06 μM. It also inhibitsCOX1withKiof 3 μM.In vitroLumiracoxib has an IC50 of 0.14 μm in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at

Mefuparib hydrochloride (MPH) is an orally active, substrate-competitive and selective PARP1/2 inhibitor with IC 50 s of 3.2 nM and 1.9 nM, respectively. Mefuparib hydrochloride induces apoptosis and possesses prominent anticancer activity in vitro